Metropolis Healthcare Ltd is the second largest Diagnostic company in India and the largest player in Western and Southern India. Metropolis Healthcare is a diagnostics company, with presence in 22 states, 3 Union Territories, and over 700 towns in India, supported by a robust network of more than 200 laboratories, 4,400 patient service centers, and over 10,000 touchpoints. Metropolis Healthcare Ltd (Formerly known as Pathnet India Private Limited) was incorporated at New Delhi on November 10, 2000.
The company has established itself as a prominent healthcare diagnostics provider with extensive operations across India and international markets. With over 35 years of experience in delivering accurate reports, Metropolis has earned the reputation of being India's most respected and only multinational chain of diagnostic centres with presence in UAE, Sri Lanka, South Africa, Kenya, Mauritius, and Ghana. Metropolis is accredited by the National Accreditation Board for Testing and Calibration Laboratories (NABL) and the College of American Pathologists (CAP), the gold standard in laboratory accreditation.
It offers a comprehensive range of more than 4,000 tests and profiles, including advanced tests for diagnosing cancer, neurological disorders, infectious diseases, and various genetic abnormalities. Metropolis has amongst the largest service menus in India offering more than 4,500 varieties of tests. Processing 15 million tests a year, Metropolis caters to more than 10,000 laboratories, hospitals, and nursing homes, as well as 200,000 doctors.
The company operates through multiple service verticals including pathology testing, clinical trials, hospital lab management, and home health services. The company offers pathology testing, imaging and nuclear medicine, clinical trials, and home health services. Products & Services: Pathology Testing Services, Corporate Wellness, Lab in Hospitals, Clinical Research Services Category: Service Provider. The company offers clinical laboratory testing, and profiles services. It also provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as various health check-up packages for men, women, senior citizens, and youth and corporates.
Metropolis Healthcare Ltd has a market capitalization of ₹9,189 Crore. The company has demonstrated strong financial performance in recent quarters with steady revenue growth and profitability.
For the financial year ended March 2025:
- Sales rose 10.23% to ₹1,331.20 Crore in the year ended March 2025, as against ₹1,207.71 Crore during the previous year ended March 2024.
- For the full year, net profit rose 13.42% to ₹144.97 Crore in the year ended March 2025, as against ₹127.82 Crore during the previous year ended March 2024.
For the quarter ended March 2025:
- Sales rose 4.32% to ₹345.29 Crore in the quarter ended March 2025, as against ₹331.00 Crore during the previous quarter ended March 2024.
- Net profit of Metropolis Healthcare declined 19.97% to ₹29.14 Crore in the quarter ended March 2025, as against ₹36.41 Crore during the previous quarter ended March 2024.
For the quarter ended December 2024 (Q3 FY25):
- Revenue from operations grew 10.9% YoY to ₹322.77 Crore.
- Profit before tax jumped 14.9% to ₹42.34 Crore compared to ₹36.85 Crore recorded in the same quarter last year.
- EBITDA stood at ₹72 Crore, registering the growth of 9.4% as compared with ₹66 Crore posted in the corresponding quarter last year. The EBITDA margin slightly decreased to 22.20% in Q3 FY25, down from 22.50% in Q3 FY24.
The Metropolis Healthcare Ltd's 52-week high share price is ₹2,306.85 and 52-week low share price is ₹1,383.70. Last 3 Years: Metropolis Healthcare Ltd share price moved up by 24.02% on BSE. The company has maintained a strong market position despite periodic volatility in the healthcare sector.
The company has been actively pursuing expansion through strategic acquisitions and organic growth. Metropolis Healthcare to acquire Dehradun-based Dr. Ahujas' Pathology for ₹35 Crore. Metropolis Histoxpert Digital Services is a wholly-owned subsidiary of Metropolis Healthcare. Dr. Ahujas' Pathology and Imaging Centre (DAPIC) operates two laboratories accredited by National Accreditation Board for Testing and Calibration Laboratories (NABL) and National Accreditation Board for Hospitals and Healthcare Providers (NABH) 11 patient service centres, and nine hospital-based centres.
The company reported strong B2C revenue growth of 15% year-on-year (YoY) in Q3 FY25. Patient volume increased by 5%, while revenue per patient (RPP) saw a robust 10% growth, driven by enhanced upselling and value delivery.
Promoter holding in Metropolis Healthcare Ltd has gone down to 48.90% as of March 2025 from 49.62% as of June 2024. The company maintains a balanced shareholding structure with significant promoter ownership while allowing for institutional and retail participation.
Metropolis follows a rigorous 8-Stage MET Protocol that ensures the most comprehensive testing for accurate and reliable reports. Today, we are one of the few laboratories that has received the CAP (College of American Pathologists), accreditation, the global gold standard in Laboratory Accreditation.
The company continues to invest in advanced technologies and automation to enhance service delivery and maintain its competitive edge in the rapidly evolving diagnostic services market. With its extensive network, strong financial performance, and commitment to quality standards, Metropolis Healthcare remains well-positioned to capitalize on the growing demand for diagnostic services in India and international markets.
